Author details

Full Name

Rita E Chen

Affiliation

ORCID

Career Start Year

2015

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
36638211	prM-reactive antibodies reveal a role for partially mature virions in dengue virus pathogenesis.	Proc Natl Acad Sci U S A	2023
38039973	A broadly reactive antibody targeting the N-terminal domain of SARS-CoV-2 spike confers Fc-mediated protection.	Cell Rep Med	2023
35347138	Monospecific and bispecific monoclonal SARS-CoV-2 neutralizing antibodies that maintain potency against B.1.617.	Nat Commun	2022
36159723	Transient leg nodules.	JAAD Case Reports	2022
35688161	mRNA vaccine boosting enhances antibody responses against SARS-CoV-2 Omicron variant in individuals with antibody deficiency syndromes.	Cell Rep Med	2022
35412328	Multivalent designed proteins neutralize SARS-CoV-2 variants of concern and confer protection against infection in mice.	Sci Transl Med	2022
35472136	An antibody targeting the N-terminal domain of SARS-CoV-2 disrupts the spike trimer.	J Clin Invest	2022
36618402	SARS-CoV-2 booster vaccination rescues attenuated IgG1 memory B cell response in primary antibody deficiency patients.	Front Immunol	2022
34921776	The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants.	Cell Host Microbe	2022
34914540	A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates.	Sci Transl Med	2022
34668780	SARS-CoV-2 Causes Lung Infection without Severe Disease in Human ACE2 Knock-In Mice.	J Virol	2022
34901783	Standardized two-step testing of antibody activity in COVID-19 convalescent plasma.	iScience	2022
34846168	Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains.	Sci Transl Med	2022
35132398	A combination of two human neutralizing antibodies prevents SARS-CoV-2 infection in cynomolgus macaques.	Med	2022
34411541	Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals.	Cell Rep	2021
34182569	SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses.	Nature	2021
33754147	A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques.	Cell Rep Med	2021
34013273	SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity.	bioRxiv	2021
33907753	A potently neutralizing anti-SARS-CoV-2 antibody inhibits variants of concern by binding a highly conserved epitope.	bioRxiv	2021
33691139	Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection.	Cell	2021
33851155	Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques.	bioRxiv	2021
33688650	Ultrapotent miniproteins targeting the receptor-binding domain protect against SARS-CoV-2 infection and disease in mice.	bioRxiv	2021
33535027	Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization.	Cell Host Microbe	2021
33532768	Genetic and structural basis for recognition of SARS-CoV-2 spike protein by a two-antibody cocktail.	bioRxiv	2021
34056628	Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions.	Cell Rep Med	2021
33791711	Assessment of serological assays for identifying high titer convalescent plasma.	medRxiv	2021
33791696	A public vaccine-induced human antibody protects against SARS-CoV-2 and emerging variants.	bioRxiv	2021
33791694	Efficacy of a Broadly Neutralizing SARS-CoV-2 Ferritin Nanoparticle Vaccine in Nonhuman Primates.	bioRxiv	2021
34268509	Multivalent designed proteins protect against SARS-CoV-2 variants of concern.	bioRxiv	2021
34216156	Assessment of serological assays for identifying high titer convalescent plasma.	Transfusion	2021
34048708	SARS-CoV-2 exacerbates proinflammatory responses in myeloid cells through C-type lectin receptors and Tweety family member 2.	Immunity	2021
34153975	In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains.	Nature	2021
33664494	Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies.	Nat Med	2021
34192518	Ultrapotent miniproteins targeting the SARS-CoV-2 receptor-binding domain protect against infection and disease.	Cell Host Microbe	2021
34329642	Tetravalent SARS-CoV-2 Neutralizing Antibodies Show Enhanced Potency and Resistance to Escape Mutations.	J Mol Biol	2021
33756110	The antigenic anatomy of SARS-CoV-2 receptor binding domain.	Cell	2021
33594356	SARS-CoV-2 variants show resistance to neutralization by many monoclonal and serum-derived polyclonal antibodies.	Res Sq	2021
34464596	A vaccine-induced public antibody protects against SARS-CoV-2 and emerging variants.	Immunity	2021
34919799	SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity.	Cell Rep	2021
34462745	Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains.	bioRxiv	2021
34981065	Monospecific and bispecific monoclonal SARS-CoV-2 neutralizing antibodies that maintain potency against B.1.617.	bioRxiv	2021
34610295	Implications of a highly divergent dengue virus strain for cross-neutralization, protection, and vaccine immunity.	Cell Host Microbe	2021
34548634	Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail.	Nat Microbiol	2021
34655519	Structural mechanism of SARS-CoV-2 neutralization by two murine antibodies targeting the RBD.	Cell Rep	2021
34481543	A potently neutralizing SARS-CoV-2 antibody inhibits variants of concern by utilizing unique binding residues in a highly conserved epitope.	Immunity	2021
34812429	Reduced antibody activity against SARS-CoV-2 B.1.617.2 delta virus in serum of mRNA-vaccinated individuals receiving tumor necrosis factor-Î± inhibitors.	Med	2021
34470866	Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques.	Proc Natl Acad Sci U S A	2021
32553273	A SARS-CoV-2 Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies.	Cell	2020
32422645	Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.	Nature	2020
32714117	Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2.	SSRN	2020